{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:31:37Z","timestamp":1761863497166},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T00:00:00Z","timestamp":1447286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00467-015-3249-5","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T11:46:57Z","timestamp":1447328817000},"page":"633-640","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases"],"prefix":"10.1007","volume":"31","author":[{"given":"Rezan","family":"Topaloglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diclehan","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrin","family":"Besbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"3249_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583\u2013596","journal-title":"N Engl J Med"},{"key":"3249_CR2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","volume":"6","author":"D Real de Asua","year":"2014","unstructured":"Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. J Clin Epidemiol 6:369\u2013377","journal-title":"J Clin Epidemiol"},{"key":"3249_CR3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361\u20132371","journal-title":"N Engl J Med"},{"key":"3249_CR4","first-page":"73","volume":"9","author":"J David","year":"1991","unstructured":"David J (1991) Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol 9:73\u201378","journal-title":"Clin Exp Rheumatol"},{"key":"3249_CR5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.gene.2011.10.012","volume":"492","author":"T Akpolat","year":"2012","unstructured":"Akpolat T, Ozkaya O, Ozen S (2012) Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 492:285\u2013289","journal-title":"Gene"},{"key":"3249_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0970-2113.48896","volume":"26","author":"R Dixit","year":"2009","unstructured":"Dixit R, Gupta R, Dave L, Prasad N, Sharma S (2009) Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis. Lung India 26:41\u201345","journal-title":"Lung India"},{"key":"3249_CR7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle\u2013Wells syndrome. Nat Genet 29:301\u2013305","journal-title":"Nat Genet"},{"key":"3249_CR8","first-page":"1991","volume":"25","author":"RE Petty","year":"1998","unstructured":"Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991\u20131994","journal-title":"J Rheumatol"},{"key":"3249_CR9","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"3249_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F (2014) Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81:112\u2013117","journal-title":"Joint Bone Spine"},{"key":"3249_CR11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/1744666X.2015.1032257","volume":"11","author":"A Woerner","year":"2015","unstructured":"Woerner A, von Scheven-Gete A, Cimaz R, Hofer M (2015) Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol 11:575\u2013588","journal-title":"Expert Rev Clin Immunol"},{"key":"3249_CR12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","volume":"10","author":"S Ozen","year":"2014","unstructured":"Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10:135\u2013147","journal-title":"Nat Rev Rheumatol"},{"key":"3249_CR13","first-page":"659","volume":"16","author":"E Giat","year":"2014","unstructured":"Giat E, Lidar M (2014) Cryopyrin-associated periodic syndrome. Isr Med Assoc J 16:659\u2013661","journal-title":"Isr Med Assoc J"},{"key":"3249_CR14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11926-014-0454-3","volume":"16","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Wallace C (2014) Judicious use of biologicals in juvenile idiopathic arthritis. Curr Rheumatol Rep 16:454","journal-title":"Curr Rheumatol Rep"},{"key":"3249_CR15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10067-005-0048-6","volume":"25","author":"C Duarte","year":"2006","unstructured":"Duarte C, Gomes C, Correia AJ, Salgado M (2006) Renal amyloidosis: an uncommon complication of juvenile idiopathic arthritis. Clin Rheumatol 25:548\u2013549","journal-title":"Clin Rheumatol"},{"key":"3249_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","volume":"72","author":"N Haar Ter","year":"2013","unstructured":"Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, Kone-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever\/Eurotraps Projects (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678\u2013685","journal-title":"Ann Rheum Dis"},{"key":"3249_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ (2014) Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 12:13","journal-title":"Pediatr Rheumatol Online J"},{"key":"3249_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","volume":"7","author":"S Urieli-Shoval","year":"2000","unstructured":"Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64\u201369","journal-title":"Curr Opin Hematol"},{"key":"3249_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","volume":"1753","author":"L Obici","year":"2005","unstructured":"Obici L, Perfetti V, Palladini G, Moratti R, Merlini G (2005) Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 1753:11\u201322","journal-title":"Biochim Biophys Acta"},{"key":"3249_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24\u201329","journal-title":"Lancet"},{"key":"3249_CR21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5858\/134.4.532","volume":"134","author":"S Sen","year":"2010","unstructured":"Sen S, Sarsik B (2010) A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. Arch Pathol Lab Med 134:532\u2013544","journal-title":"Arch Pathol Lab Med"},{"key":"3249_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/ki.2014.368","volume":"87","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Hawkins PN, Lachmann HJ (2015) Emerging treatments for amyloidosis. Kidney Int 87:516\u2013526","journal-title":"Kidney Int"},{"key":"3249_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633\u2013652","journal-title":"Nat Rev Drug Discov"},{"key":"3249_CR24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nri3261","volume":"12","author":"H Park","year":"2012","unstructured":"Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570\u2013580","journal-title":"Nat Rev Immunol"},{"key":"3249_CR25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA, Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 64:1001\u20131010","journal-title":"Arthritis Care Res"},{"key":"3249_CR26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998\u20131006","journal-title":"Lancet"},{"key":"3249_CR27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3899\/jrheum.130924","volume":"41","author":"C Aoki","year":"2014","unstructured":"Aoki C, Inaba Y, Choe H, Kaneko U, Hara R, Miyamae T, Imagawa T, Mori M, Oba MS, Yokota S, Saito T (2014) Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol 41:1171\u20131177","journal-title":"J Rheumatol"},{"key":"3249_CR28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, Delfino L, Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M, Vecchi A, Ravelli A, Martini A, Rubartelli A (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505\u20131515","journal-title":"Arthritis Rheum"},{"key":"3249_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63:545\u2013555","journal-title":"Arthritis Rheum"},{"key":"3249_CR30","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO; PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396\u20132406","journal-title":"N Engl J Med"},{"key":"3249_CR31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11882-008-0047-1","volume":"8","author":"RL Glaser","year":"2008","unstructured":"Glaser RL, Goldbach-Mansky R (2008) The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 8:288\u2013298","journal-title":"Curr Allergy Asthma Rep"},{"key":"3249_CR32","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jimenez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70:2095\u20132102","journal-title":"Ann Rheum Dis"},{"key":"3249_CR33","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00296-010-1474-6","volume":"32","author":"N Alpay","year":"2012","unstructured":"Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A (2012) Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 32:3277\u20133279","journal-title":"Rheumatol Int"},{"key":"3249_CR34","unstructured":"Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ (2015) Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and systemic autoinflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol PMID: 26120866"},{"key":"3249_CR35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ndt\/gfn646","volume":"24","author":"C Moser","year":"2009","unstructured":"Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, Lachmann HJ, Lang U, Kovarik J (2009) Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676\u2013678","journal-title":"Nephrol Dial Transplant"},{"key":"3249_CR36","author":"ZB Ozcakar","year":"2014","unstructured":"Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Sukur ED, Ekim M, Yalcinkaya F (2014) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. doi: 10.1007\/s10067-014-2772-2","journal-title":"Clin Rheumatol"},{"key":"3249_CR37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10067-013-2481-2","volume":"34","author":"R Scarpioni","year":"2015","unstructured":"Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L, Lazzaro A (2015) Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol 34:1311\u20131316","journal-title":"Clin Rheumatol"},{"key":"3249_CR38","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1073\/pnas.1103681108","volume":"108","author":"S Stojanov","year":"2011","unstructured":"Stojanov S, Lapidus S, Chitkara P, Feder H, Salazar JC, Fleisher TA, Brown MR, Edwards KM, Ward MM, Colbert RA, Sun HW, Wood GM, Barham BK, Jones A, Aksentijevich I, Goldbach-Mansky R, Athreya B, Barron KS, Kastner DL (2011) Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 108:7148\u20137153","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3249_CR39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.37827","volume":"65","author":"T Lane","year":"2013","unstructured":"Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ (2013) AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65:1116\u20131121","journal-title":"Arthritis Rheum"},{"key":"3249_CR40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00467-003-1129-x","volume":"18","author":"A Oner","year":"2003","unstructured":"Oner A, Erdogan O, Demircin G, Bulbul M, Memis L (2003) Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol 18:521\u2013526","journal-title":"Pediatr Nephrol"},{"key":"3249_CR41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12882-015-0046-0","volume":"16","author":"E Castano","year":"2015","unstructured":"Castano E, Palmer MB, Vigneault C, Luciano R, Wong S, Moeckel G (2015) Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome. BMC Nephrol 16:64","journal-title":"BMC Nephrol"},{"key":"3249_CR42","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","volume":"92","author":"GA Tennent","year":"1995","unstructured":"Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299\u20134303","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3249_CR43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","volume":"148","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148:760\u2013767","journal-title":"Br J Haematol"},{"key":"3249_CR44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254\u2013259","journal-title":"Nature"},{"key":"3249_CR45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93\u201397","journal-title":"Nature"},{"key":"3249_CR46","first-page":"277","volume":"16","author":"ME Pepys-Vered","year":"2014","unstructured":"Pepys-Vered ME, Pepys MB (2014) Targeted treatment for amyloidosis. Isr Med Assoc J 16:277\u2013280","journal-title":"Isr Med Assoc J"},{"key":"3249_CR47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2014","unstructured":"Westermark GT, F\u00e4ndrich M, Westermark P (2014) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10:321\u2013344","journal-title":"Annu Rev Pathol"},{"key":"3249_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.gene.6364070","volume":"5","author":"E Aganna","year":"2004","unstructured":"Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF (2004) Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 5:289\u2013293","journal-title":"Genes Immun"},{"key":"3249_CR49","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.24735","volume":"61","author":"L Obici","year":"2009","unstructured":"Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 61:1435\u20131440","journal-title":"Arthritis Rheum"},{"key":"3249_CR50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00296-009-1331-7","volume":"32","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Lucherini OM, Simonini G, Galeazzi M, Baldari CT, Cimaz R (2012) Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatol Int 32:465\u2013467","journal-title":"Rheumatol Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3249-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-015-3249-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3249-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:53:24Z","timestamp":1718193204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-015-3249-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["3249"],"URL":"https:\/\/doi.org\/10.1007\/s00467-015-3249-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}